Ribociclib (LEE011)

For research use only.

Catalog No.S7440

59 publications

Ribociclib (LEE011) Chemical Structure

CAS No. 1211441-98-3

Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.

Selleck's Ribociclib (LEE011) has been cited by 59 publications

Purity & Quality Control

Choose Selective CDK Inhibitors

Biological Activity

Description Ribociclib (LEE011) is an orally available, and highly specific inhibitor of CDK4 and CDK6 with IC50 of 10 nM and 39 nM. Phase 3.
Features Orally bioavailable CDK4/6-selective inhibitor that has been tested in Phase III clinical trials for treatment of advanced breast cancer.
Targets
CDK4 [2]
(Cell-free assay)
CDK6 [2]
(Cell-free assay)
10 nM 39 nM
In vitro

LEE011, as dual CDK4/CDK6 inhibitor, significantly inhibits the growth of 12 of 17 neuroblastoma cell lines with mean IC50 of 307 nM. The growth inhibition of neuroblastoma cell lines is primarily cytostatic and is mediated by a G1 cell-cycle arrest and cellular senescence. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DFSP105 Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYSyOEBp NFLoVodIUTVyPUK3OkBvVQ>? NGrPWpY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi1NlA2QCd-MkW4OVIxPTh:L3G+
Myoblast MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYDOUZBPPzJiaB?= M4G4[mlEPTB;MUCzOUBvVQ>? NWnTe3puRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVA{PzVpPkK1PFExOzd3PD;hQi=>
IMRS MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPZR5g4OiCq MWHJR|UxRTh5MzDuUS=> NVvReIpoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4NVA{PzVpPkK1PFExOzd3PD;hQi=>
SKNAS NH;aPFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHPd3Y4OiCq MnXDTWM2OO,:nkGwNFAxKG6P NH;QVVc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUixNFM4PSd-MkW4NVA{PzV:L3G+
Rh28 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrsbVU4OiCq NEPMRXpKSzVyPUi0OUBvVQ>? MnvaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCzO|UoRjJ3OEGwN|c2RC:jPh?=
Rh41 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjubmk4OiCq NYT6R281UUN3ME23NVg4KG6P MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMEO3OUc,OjV6MUCzO|U9N2F-
CW9019 M3HubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV[3NkBp MXvJR|UxRTl7MUKgcm0> MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPThzMEO3OUc,OjV6MUCzO|U9N2F-
Rh5 MnnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXK3NkBp M3r5ZWlEPTExvK6xNFAxOCCwTR?= MmO2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6MUCzO|UoRjJ3OEGwN|c2RC:jPh?=
Rh30 NHrJRnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnOO|IhcA>? NG\3N5hKSzVy78{eNVAxODBibl2= M2qwVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEGwN|c2Lz5{NUixNFM4PTxxYU6=
778 NF7OenhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDsWXA4OiCq NIH0dXdqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 MmnCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
449 M3nu[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3XO|IhcA>? M1fkO4lvcGmkaYTzJINmdGxiZ4Lve5RpKGSxc3Wg[IVx\W6mZX70cJk> MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{OES2PUc,OjVyMki0Olk9N2F-
LP3 M1HLT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XLR|czKGh? Mo[3bY5pcWKrdIOgZ4VtdCCpcn;3eIgh\G:|ZTDk[ZBmdmSnboTsfS=> NF76eoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyPFQ3QSd-MkWwNlg1Pjl:L3G+
LP6 Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWm3NkBp NHG5[5dqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M1\ZVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK4OFY6Lz5{NUCyPFQ3QTxxYU6=
LP8 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV[3NkBp NF\3RlZqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6 M3HyXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MEK4OFY6Lz5{NUCyPFQ3QTxxYU6=
LPS141 NEDhWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q2XlczKGh? NXm1V|FGcW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>? MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{OES2PUc,OjVyMki0Olk9N2F-
778 MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXqzMlM{KM7:TR?= NF7tdXgzPCCq NYXIVWwz\GWlcnXhd4V{KHSqZTDwdo9xd3K2aX;uJI9nKGOnbHzzJIlvKFNicHjhd4U> NFHGWIg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyPFQ3QSd-MkWwNlg1Pjl:L3G+
449 Mn[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3FN{4{OyEQvF2= NVrSTpZ{OjRiaB?= MVPk[YNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZ4VtdHNiaX6gV{BxcGG|ZR?= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTB{OES2PUc,OjVyMki0Olk9N2F-
LP3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLIN{4{OyEQvF2= NInLRoIzPCCq MmjQ[IVkemWjc3XzJJRp\SCycn;wc5J1cW:wIH;mJINmdGy|IHnuJHMheGijc3W= Mm[1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
LP6 M13oOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoTjN{4{OyEQvF2= NXn3XHBGOjRiaB?= M1PZUYRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBk\WyuczDpckBUKHCqYYPl NHjWcZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUCyPFQ3QSd-MkWwNlg1Pjl:L3G+
LP8 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vyTFMvOzNizszN M{\jS|I1KGh? NGDlPIZl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[2WubIOgbY4hWyCyaHHz[S=> MlmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyMki0OlkoRjJ3MEK4OFY6RC:jPh?=
LPS141 NFfGdXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEHnbnY{NjN|IN88US=> NVfobmV[OjRiaB?= NIjMOYpl\WO{ZXHz[ZMhfGinIIDyc5BwenSrb36gc4Yh[2WubIOgbY4hWyCyaHHz[S=> NVv3b3I3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwNlg1PjlpPkK1NFI5PDZ7PD;hQi=>
IMR5 M{DIS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX60NXA3OjRiaB?= MlroSG1UVw>? M1;EUmlEPTB;MUK2JI5O MlPHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO|koRjJ2MES1NVc6RC:jPh?=
BE2C M3PjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TFT|I1KGh? NYjadGtITE2VTx?= M{nxd2lEPTB;MUO0JI5O MmnHQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO|koRjJ2MES1NVc6RC:jPh?=
1643 NWK0R25ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUWyOEBp NIfBZlRFVVOR MnfFTWM2OD1zNEegcm0> NELOUlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
SKNSH MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfuNlQhcA>? NYS5S3J{TE2VTx?= M3ewVmlEPTB;MUS4JI5O NXPwPG5ZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
SY5Y NFfxXXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEToTVkzPCCq M3XFWWROW09? MnjTTWM2OD1zNUSgcm0> M{nqT|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
NGP NHzwZZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYCyOEBp MV3EUXNQ MXTJR|UxRTF5NTDuUS=> NGrCRWw9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
KELLY MlfWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnu0NlQhcA>? NEWySoxFVVOR M2LkcGlEPTB;MkKwJI5O NULXdXN6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
CHP134 NV[3V5ViT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUiyOEBp MoCySG1UVw>? M3jZe2lEPTB;MkezJI5O NV23cVk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
NLF M1rrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfiOVUzPCCq M3v3XmROW09? NW\xVXU1UUN3ME2zNlghdk1? NEnTRo89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEC0OVE4QSd-MkSwOFUyPzl:L3G+
LAN5 NUm5XmFFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33CXlI1KGh? NGn4N2hFVVOR NU\odYZKUUN3ME20Nlkhdk1? NUPz[VZoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
NB69 MlTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWWyOEBp MmPKSG1UVw>? MXfJR|UxRTd|ODDuUS=> NUDFWnVXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
SKNDZ MkDoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoT3NlQhcA>? NWnMW4dHTE2VTx?= NI\BUnpKSzVyPUiwNUBvVQ>? M{G3elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MES1NVc6Lz5{NEC0OVE4QTxxYU6=
NBSD MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6yOEBp NE\MT5BFVVOR M2XjOGlEPTB;MUmwNEBvVQ>? MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO|k9N2F-
SKNF1 NH73dVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELPRmUzPCCq M1T6WmROW09? NHTWfVdKSzVyPUO1NFAhdk1? NYHVfpZzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
EBC1 M4HD[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KzZlI1KGh? MoKySG1UVw>? MlK0TWM2OD14NECwJI5O MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDB2NUG3PUc,OjRyNEWxO|k9N2F-
SKNAS MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1W1XFI1KGh? MVrEUXNQ NWjFc4ZHUUN3MP-8olExODByIH7N NWXmeY5TRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOFUyPzlpPkK0NFQ2OTd7PD;hQi=>
NB16 NFH1UFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvMPFN3OjRiaB?= MWLEUXNQ NIPWOVBKSzVy78{eNVAxODBibl2= Mm\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO|koRjJ2MES1NVc6RC:jPh?=
RPE1 M4HBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mni5NlQhcA>? MVHEUXNQ NVvQR3E1UUN3MP-8olExODByIH7N MmHZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjRyNEWxO|koRjJ2MES1NVc6RC:jPh?=
Sf21 MYPGeY5kfGmxbjDhd5NigQ>? MnXsNVAhdWmwcx?= NHXLOIRKdmirYnn0bY9vKG:oIILlZ49u[mmwYX70JIh2dWGwIH\1cIwhdGWwZ4ToJG4ufGW{bXnuZYwhT1OWLYTh[4dm\CCFRFu0M2N6[2yrbj3EN{Bkdy2neIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhe2Z{MTDj[YxteyC3c3nu[{BT[iC|dXLzeJJifGViaX6gdJJme2WwY3Wgc4YhY2ejbX3hN|NRZUGWUDDh[pRmeiBzMDDtbY5{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcochdWW2aH;kMEBKSzVyIE2gNE4xOTNizszNMi=> MWS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVzOEOxNkc,Ojl3MUizNVI9N2F-
Sf21 NXvYfVdPTnWwY4Tpc44h[XO|YYm= NYfQPYlOOTBibXnudy=> M3zNSmlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgbJVu[W5iZoXscEBt\W6pdHigR{11\XKvaX7hcEA3UGm|LYTh[4dm\CCFRFu5M2N6[2yrbj3UNUBkdy2neIDy[ZN{\WRiaX6gZoFkfWyxdnnyeZMhcW6oZXP0[YQhe2Z{MTDj[YxteyC3c3nu[{BRTEu2aXTlJJN2[nO2cnH0[UBqdiCycnXz[Y5k\SCxZjDb[4FudWF|M2DdRXRRKGGodHXyJFExKG2rboOgZpkhe2OrboTpcIxifGmxbjDjc5VvfGmwZzDt[ZRpd2RuIFnDOVAhRSByLkG5O{DPxE1w M2nMXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N|EzLz5{OUWxPFMyOjxxYU6=
HepG2 NW\VfJhlSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= MVy3NkBpenN? NHrub21CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxVcXSncj3HcI8h[XO|YYmsJGVEPTBiPTCwMlI5PjJizszNMi=> M{XaN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEC3PVc2Lz5{OUSwO|k4PTxxYU6=
SEM MVTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MlnOO|IhcHK| NFS1W3dCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGPFUUBk\WyuczDh[pRmeiB5MjDodpMh[nliQ3XsWIl1\XJvR3zvJIF{e2G7LDDFR|UxKD1iMD60OlA2KM7:TT6= NVnZbnh[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PzVpPkK5OFA4QTd3PD;hQi=>
KOPN8 NGT5bo5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= Ml7sO|IhcHK| NFfCNoJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFvPVG45KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDD[YxVcXSncj3HcI8h[XO|YYmsJGVEPTBiPTCwMlUxODhizszNMi=> MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTRyN{m3OUc,Ojl2MEe5O|U9N2F-
NCI-H1299 MX;DfZRwfG:6aXPpeJkh[XO|YYm= NF[xZWs4OiCqcoO= NGq2XVlEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBPS0lvSEGyPVkh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKGmwIHPlcIwhfmmjYnnsbZR6KGGodHXyJFczKGi{czDifUBES0t6IHHzd4F6NCCLQ{WwJF0hPS52NjFOwG0v MnX5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N|EzRC:jPh?=
T47D NFzWZ2VIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NUHkS3lWPzJiaILz M{\jc2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJHQ1P0RiY3XscJMhcW6ldXLheIVlKG[xcjC3NkBpenNiYomgR2NMQCCjc4PhfUwhUUN3MDC9JFYvOjJ5IN88UU4> MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDZ3MUm3PUc,Ojh4NUG5O|k9N2F-
T47D NHnuZlNEgXSxdH;4bYNqfHliYYPzZZk> MnS0O|IhcHK| MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDUOFdFKGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkA4OiCqcoOgZpkhS0ONODDhd5NigSxiSVO1NEA:KDZwMkOg{txONg>? MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVzOEOxNkc,Ojl3MUizNVI9N2F-
H1299 MU\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M2DldlczKGi{cx?= M3;xb2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGgyOjl7IHPlcIx{KGmwY4XiZZRm\CCob4KgO|IhcHK|IHL5JGNEUzhiYYPzZZktKEmFNUCgQUA4NjZ|NzFOwG0v Ml3QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh4NUG5O|koRjJ6NkWxPVc6RC:jPh?=
KOPN8 NFvVZlhCeG:ydH;zbZMh[XO|YYm= NV72cnhPOC53IIXN NIixc2Q{KGi{cx?= MnHoTY5lfWO2aX;uJI9nKGGyb4D0c5NqeyCrbjDoeY1idiCNT2DOPEBk\WyuczDhd5Nme3OnZDDhd{B2eHKnZ4XsZZRqd25ib3[gZ4xm[X[nZDDQRXJRKGyndnXsJIF1KDBwNTD1UUBi\nSncjCzJIhzeyCkeTDX[ZN1\XKwIHLsc5Qh[W6jbInzbZM> NWr3U|VMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0NFc6PzVpPkK5OFA4QTd3PD;hQi=>
KOPN8 NIrqUVVCeG:ydH;zbZMh[XO|YYm= M4nzfFAvPSC3TR?= NVHuZYt2OjRiaILz NH7BR3JKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m|IHnuJIh2dWGwIFvPVG45KGOnbHzzJIF{e2W|c3XkJIF{KHWycnXneYxifGmxbjDv[kBkdGWjdnXkJHBCWlBibHX2[Ywh[XRiMD61JJVOKHC{ZT30doVifGWmIIfpeIghVkGFIH\vdkAyKGi{IHHu[EBu\WG|dYLl[EBi\nSncjCyOEBpenNiYomgW4V{fGW{bjDicI91KGGwYXz5d4l{ NH;Rb5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSwO|k4PSd-Mkm0NFc6PzV:L3G+
Hep3B MnX6R4VtdCCleXPs[UBie3OjeR?= NHz2WWszPCCqcoO= NETDWXhE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBJ\XB|QjDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS|EheGijc3WgZYZ1\XJiMkSgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2com= MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTVzOEOxNkc,Ojl3MUizNVI9N2F-
HepG2 MWPD[YxtKGO7Y3zlJIF{e2G7 MXWyOEBpenN? NFq5T|FE\WyuIHP5Z4xmKGG{cnXzeEBqdiCqdX3hckBJ\XCJMjDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS|EheGijc3WgZYZ1\XJiMkSgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2com= M3foSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N|EzLz5{OUWxPFMyOjxxYU6=
A549 MXHD[YxtKGO7Y3zlJIF{e2G7 MWKyOEBpenN? NVyxPXM6S2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDhZ4N2dXWuYYTpc44h[XRiR{CvS|EheGijc3WgZYZ1\XJiMkSgbJJ{KGK7IIDyc5Bq\Gm3bTDpc4Rq\GVic4ThbY5qdmdiYnHz[YQh\myxdzDjfZRwdWW2com= NG\jWpQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWxPFMyOid-Mkm1NVg{OTJ:L3G+
NCI-H460 NX\HbFNYS2WubDDjfYNt\SCjc4PhfS=> NFzMfm8zPCCqcoO= Moq0R4VtdCCleXPs[UBienKnc4SgbY4hcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYYPz[ZN{\WRiYYOgZYNkfW23bHH0bY9vKGG2IFewM2cyKHCqYYPlJIFnfGW{IEK0JIhzeyCkeTDwdo9xcWSrdX2gbY9lcWSnIIP0ZYlvcW6pIHLhd4VlKG[ub4egZ5l1d22ndIL5 M2fFN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N|EzLz5{OUWxPFMyOjxxYU6=
T47D MmLDR4VtdCCleXPs[UBie3OjeR?= NFLnUnczPCCqcoO= M1XmcWNmdGxiY4njcIUh[XK{ZYP0JIlvKGi3bXHuJHQ1P0RiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJIF1KEdyL1exJJBp[XOnIHHmeIVzKDJ2IHjyd{BjgSCycn;wbYRqfW1iaX;kbYRmKHO2YXnubY5oKGKjc3XkJIZtd3diY4n0c41mfHK7 NHrobIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUWxPFMyOid-Mkm1NVg{OTJ:L3G+
MDA-MB-231 NH3Vfo1E\WyuIHP5Z4xmKGG|c3H5 M3nnZ|I1KGi{cx?= NVP0elJOS2WubDDjfYNt\SCjcoLld5QhcW5iaIXtZY4hVUSDLV3CMVI{OSClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzBxR{GgdIhie2ViYX\0[ZIhOjRiaILzJIJ6KHC{b4Dp[Il2dSCrb3Tp[IUhe3SjaX7pcoch[mG|ZXSg[oxwfyCleYTvcYV1enl? M4jublxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUG4N|EzLz5{OUWxPFMyOjxxYU6=
Fluc-labeled 4T1 M2T4Z2FvfGm2dX3vdkBie3OjeR?= NUnjVldDOTNyIH3nM4to NVXYZVN1OThiZHH5dy=> NXH2SVVbSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhdW:3c3WgSox2[y2uYXLlcIVlKDSWMTDj[YxteyCrbYDsZY51\WRiaX6gRoFt[i:lIH3veZNmKGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckB1fW2xcjD3[YlocHRiYYSgNVMxKG2pL3vnMEBqeCCjZH3pcol{fGW{ZXSg[IFqdHliZn;yJFE5KGSjeYOgcYVie3W{ZXSgZYZ1\XJiODD0c{AzPSCmYYnz MlfqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl3MUizNVIoRjJ7NUG4N|EzRC:jPh?=
T47D M2ixemNmdGxiY4njcIUh[XO|YYm= NXHoRoE2OjRiaILz NIXvcFFKdmS3Y4Tpc44hd2ZiY3XscEBkgWOuZTDhdpJme3RiaX6gbJVu[W5iVES3SEBk\WyuczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCJMD;HNUBxcGG|ZTDhZ4N2dXWuYYTpc44hcW6ldXLheIVlKG[xcjCyOEBpenNiYomg[oxwfyCleYTvcYV1enl? M1LtNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6NkWxPVc6Lz5{OE[1NVk4QTxxYU6=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
pRb(S807) / Rb / p53 / Cyclin E / Cyclin D1 / CDK4 / CDK6 / p27 / p21 / PARP; 

PubMed: 29789630     


Effect of ribociclib on pRB and G1 cell cycle regulating protein expressions in C666-1 and HK1 cells. Cells were treated with ribociclib in 2 concentrations, one of them near their corresponding IC50, for 24 and 48 hours. Phosphorylation of Rb in all cell䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖帉痖Ѐ瑖堘𢡄빢᎒ՂĀ鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤瘯Ɖ⟸෕䐺痖暼瘿⟸෕ᾰƌ ⟸෕Ð㺣痖⟸෕€𢡄⟼෕€䀷痗⟼෕౴⟼෕

29789630
Growth inhibition assay
Cell viability ; 

PubMed: 26390342     


Effects of palbociclib and ribociclib on viability of H157, H2170, H520 and H596 cells after 72 hours of drug treatment and IC50 values for inhibition of cell viability.

26390342
In vivo

LEE011 (200 mg/kg daily, p.o.) significantly causes tumor growth delay in mice harboring the BE2C or 1643 xenografts with no weight loss or other signs of toxicity. [1]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: BE2C, IMR5, 1643, SY5Y, CHP134, SKNSH, NGP, KELLY, LAN5, NLF, NB69, SKNDZ, NBSD, NBLS, SKNFI, EBC1, SKNAS, NB16, RPE1 cell lines.
  • Concentrations: 10 μM
  • Incubation Time: ~100 hours
  • Method:

    A panel of neuroblastoma cell lines, selected based upon prior demonstration of substrate adherent growth, is plated in triplicate on the Xcelligence Real-Time Cell Electronic Sensing system and treated 24 hours later with a four-log dose range of inhibitor or with a dimethyl sulfoxide (DMSO) control. Cell indexes are monitored continuously for ~100 hours, and IC50 values are determined as follows: growth curves are generated by plotting the cell index as a function of time and are normalized to the cell index at the time of treatment for a baseline cell index of 1. The area under the normalized growth curve from the time of treatment to 96 hours posttreatment is then calculated using a baseline area of 1 (the cell index at the time of treatment). Areas are normalized to the DMSO control, and the resulting data are analyzed using a nonlinear log inhibitor versus normalized response function. All experiments are repeated at least once.


    (Only for Reference)
Animal Research:

[1]

- Collapse
  • Animal Models: Mice bearing BE2C, NB-1643, or EBC1 xenografts.
  • Dosages: ~200 mg/kg daily
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 7 mg/mL (16.1 mM)
Water Insoluble
Ethanol Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 434.54
Formula

C23H30N8O

CAS No. 1211441-98-3
Storage powder
in solvent
Synonyms N/A
Smiles CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04657679 Recruiting Drug: Ribociclib Breast Cancer Georgetown University|Medstar Health Research Institute|Breast Cancer Research Foundation|Georgetown-Howard Universities Center for Clinical and Translational Science (GHUCCTS) May 20 2021 --
NCT04315233 Recruiting Drug: Ribociclib|Drug: Belinostat Metastatic Breast Cancer|Recurrent Ovarian Carcinoma University of Utah|Novartis|Acrotech Biopharma October 29 2020 Phase 1
NCT04417621 Recruiting Drug: LXH254|Drug: LTT462|Drug: Trametinib|Drug: Ribociclib Melanoma Novartis Pharmaceuticals|Novartis October 30 2020 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

CDK Signaling Pathway Map

Related CDK Products

Tags: buy Ribociclib (LEE011) | Ribociclib (LEE011) supplier | purchase Ribociclib (LEE011) | Ribociclib (LEE011) cost | Ribociclib (LEE011) manufacturer | order Ribociclib (LEE011) | Ribociclib (LEE011) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID